Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Edesa Biotech"},{"company":"Devonian Health Group","sponsor":"PurGenesis Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine\u2122 in Mild to Moderate AD","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Devonian Health Group"},{"company":"Edesa Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Reports Positive Interim Results in Dermatitis Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Edesa Biotech"},{"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Edesa Biotech Marks Enrollment Milestone in Dermatitis Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Edesa Biotech"},{"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Health Group Announces the Journal of Drugs in Dermatology Acceptance for Publication of Thykamine\u2122 Positive Phase 2 Clinical Trial Results in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Devonian Health Group"}]

Devonian Health Group

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Devonian Health Group Announces the Journal of Drugs in Dermatology Acceptance for Publication of Thykamine™ Positive Phase 2 Clinical Trial Results in Atopic Dermatitis

Details:

The benefit of PUR0110 (Thykamine) cream 0.10% was supported by a statistically significant effect on the primary and secondary endpoints of Body Surface Area (BSA), pruritis, and Patient-Oriented Eczema Measure score (POEM).

Lead Product(s): Thykamine

Therapeutic Area: Dermatology Product Name: PUR0110

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 26, 2022

ASK
US

Upload
your Pipeline Activity

Edesa Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Edesa Biotech Marks Enrollment Milestone in Dermatitis Study

Details:

EB01, is an investigational medicine that contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor met primary efficacy endpoint, which is the mean percent change from baseline on the CDSI at day 29.

Lead Product(s): EB01

Therapeutic Area: Dermatology Product Name: EB01

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: JSS Medical Research

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 01, 2021

ASK
US

Upload
your Pipeline Activity

Edesa Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Edesa Biotech Reports Positive Interim Results in Dermatitis Trial

Details:

EB01 is designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred, the company believes that the drug could potentially exert a powerful anti-inflammatory effect without the safety concerns of steroids.

Lead Product(s): EB01

Therapeutic Area: Dermatology Product Name: EB01

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2021

ASK
US

Upload
your Pipeline Activity

Edesa Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone

Details:

EB01 contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor. Edesa reported that all 46 subjects in the first cohort have been randomized and dosed with either Edesa's EB01 topical treatment or a placebo cream.

Lead Product(s): EB01

Therapeutic Area: Dermatology Product Name: EB01

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: JSS Medical Research

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 09, 2021

ASK
US

Upload
your Pipeline Activity

Devonian Health Group

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Mild to Moderate AD

Details:

According to the results from the study, Thykamine at 0.1% showed significant improvement in skin clearance versus placebo at all measured timelines, thereby meeting the primary endpoint. It showed a fast onset of the therapeutic effect.

Lead Product(s): Thykamine

Therapeutic Area: Dermatology Product Name: PUR0110

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: PurGenesis Technologies

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 18, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY